ArticlePharmacoEconomics2002

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.

Max Brosa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.